Cargando…

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although most chronic phase CML patients treated with imatinib as first-line therapy maintain excellent durable responses, patients who have progressed to advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowan-Jacob, Sandra W., Fendrich, Gabriele, Floersheimer, Andreas, Furet, Pascal, Liebetanz, Janis, Rummel, Gabriele, Rheinberger, Paul, Centeleghe, Mario, Fabbro, Doriano, Manley, Paul W.
Formato:	Texto
Lenguaje:	English
Publicado:	International Union of Crystallography 2006
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483489/ https://www.ncbi.nlm.nih.gov/pubmed/17164530 http://dx.doi.org/10.1107/S0907444906047287

Ejemplares similares

Myelogenic Leukaemia
Publicado: (1915)

Immunotherapy for Acute Myelogenous Leukaemia
por: Powles, R. L., et al.
Publicado: (1973)

Myelogenous Leukæmia and Its Treatment
por: Debove,
Publicado: (1910)

Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
por: Zuhrie, S. R., et al.
Publicado: (1980)

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
por: Hu, C. W., et al.
Publicado: (2019)

Factors influencing prognosis in adults with acute myelogenous leukaemia.
por: Crowther, D., et al.
Publicado: (1975)

Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.
por: Cocks, P., et al.
Publicado: (1977)

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
por: Harris, R., et al.
Publicado: (1978)

Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia
por: Lee, C-Y, et al.
Publicado: (2007)

Cytogenetic analysis of leukaemic colonies from acute and chronic myelogenous leukaemia.
por: Trent, J. M., et al.
Publicado: (1983)

In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
por: Marie, J. P., et al.
Publicado: (1988)

Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside.
por: Potter, C. G., et al.
Publicado: (1980)

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia
por: Dalley, C D, et al.
Publicado: (2001)

Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
por: Lister, T. A., et al.
Publicado: (1977)

Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India
por: Anand, Maninder Singh, et al.
Publicado: (2012)

OGG1 rs1052133 Polymorphism and Genetic Susceptibility to Chronic Myelogenous Leukaemia
por: Hassan, Fathelrahman M
Publicado: (2019)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

Growth inhibitory effects of interferon on blast cells from patients with acute myelogenous leukaemia.
por: Rohatiner, A. Z.
Publicado: (1984)

Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia
por: Ghosn, Youssef, et al.
Publicado: (2019)

Familial platelet disorders with a predisposition to acute myelogenous leukaemia: a RUNX1 update
por: Rossini, J, et al.
Publicado: (2012)

Synthesis and biological evaluation of dithiocarbamate esters of parthenolide as potential anti-acute myelogenous leukaemia agents
por: Ding, Yahui, et al.
Publicado: (2018)

The lysophospholipase D enzyme Gdpd3 is required to maintain chronic myelogenous leukaemia stem cells
por: Naka, Kazuhito, et al.
Publicado: (2020)

Circulating promastocytes and atypical mast cells in systemic mastocytosis associated with acute myelogenous leukaemia transformation
por: Altohami, Mohammed O. A., et al.
Publicado: (2021)

Highly precise breakpoint detection of chromosome balanced translocation in chronic myelogenous leukaemia: Case series
por: Yang, Chuanchun, et al.
Publicado: (2022)

Partial characterization of a membrane antigen which exhibits specificity for cells of patients with acute myelogenous leukaemia.
por: Shipman, R., et al.
Publicado: (1983)

Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.
por: Sedlmayr, P., et al.
Publicado: (1992)

A Massive Right Atrial Mass in Chronic Myelogenous Leukaemia: A Case Report and Literature Review
por: Benjanuwattra, Juthipong, et al.
Publicado: (2022)

Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey
por: Kodama, Yuko, et al.
Publicado: (2012)

Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor
por: Corrado, Chiara, et al.
Publicado: (2016)

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
por: Perrotti, D, et al.
Publicado: (2006)

Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells
por: Naka, Kazuhito, et al.
Publicado: (2015)

Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery
por: Yang, Mingli, et al.
Publicado: (2014)

Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
por: Powles, R. L., et al.
Publicado: (1977)

Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia
por: Senda, Miho, et al.
Publicado: (2016)

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia
por: Schaefer, Bianca, et al.
Publicado: (2017)

Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia
por: Von Laffert, Maximilian, et al.
Publicado: (2016)

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
por: Hillmann, Petra, et al.
Publicado: (2019)

Chemical characterization of non‐psychoactive Cannabis sativa L. extracts, in vitro antiproliferative activity and induction of apoptosis in chronic myelogenous leukaemia cancer cells
por: Anceschi, Lisa, et al.
Publicado: (2022)

Mellitin peptide quantification in seasonally collected crude bee venom and its anticancer effects on myelogenous K562 human leukaemia cell line
por: Obeidat, Maher, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0agua1fajl6hb8atg4ohvq4brh